Ranbaxy Transfers Atorvastatin, Tamsulosin Filings To Ohm Labs While Valacyclovir Rakes Big Gains
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Ranbaxy - the Indian affiliate of Daiichi Sankyo - is believed to have transferred its abbreviated new drug application filing for Lipitor to its New Jersey-based Ohm Labs facility, after U.S. FDA imposed import restrictions last summer on two of its biggest manufactuirng facilities in India
You may also be interested in...
Ranbaxy-Teva Atorvastatin Mystery Deal Decoded: Many Likely Scenarios Aimed At “On Time” Launch
Industry sources tell PharmAsia News that Ranbaxy forged the Teva Lipitor deal as a back-up plan, one that could prove costly for Ranbaxy.
Ranbaxy-Teva Atorvastatin Mystery Deal Decoded: Many Likely Scenarios Aimed At “On Time” Launch
Industry sources tell PharmAsia News that Ranbaxy forged the Teva Lipitor deal as a back-up plan, one that could prove costly for Ranbaxy.
Ranbaxy Launches AG Version Of Caduet As CEO Likens Lipitor Deal With Teva To An Insurance Policy
Both Ranbaxy and Mylan appear to have agreed to sell all doses of Caduet under separate authorized generic deals with Pfizer.